IntroductIon
Mucopolysaccharidosis I (MPS I) is an autosomal recessive disease caused by a deficiency of α-l-iduronidase (IDUA; EC 3.2.1.76). 1 It results in the accumulation of the glycosaminoglycans (GAGs) heparan and dermatan sulfate, and has an incidence of 1:100,000 live births. 2 Patients with severe disease (Hurler syndrome; OMIM #607014) have skeletal deformities, hearing and vision abnormalities, cardiac disease, and mental retardation. MPS I is currently treated with hematopoietic stem cell (HSC) transplantation or enzyme replacement therapy (ERT). HSC transplantation has reduced the manifestations of disease in mice, 3 dogs, 4 and humans 5 with MPS I. The likely mechanism is migration of transplant-derived blood cells into organs, where the cells secrete enzyme modified with mannose 6-phosphate (M6P) that can be taken up by adjacent cells via the M6P receptor (M6PR). HSC transplantation is limited by the need for a compatible donor and the risks and costs of the procedure. ERT involves the intravenous injection of M6P-modified enzyme, which can diffuse into organs and be internalized via the M6PR. 6 ERT has been therapeutic in cats, 7 dogs, 8 and humans 9 with MPS I. Difficulties with ERT include the need for infusion once a week and a cost of more than $10,000 per kg body weight per year.
Gene therapy has been successfully used to treat MPS in animal models. 10 HSC-directed gene therapy to adults reduces the manifestations of MPS I in mice 3 in a similar way to HSC transplantation. As an alternative treatment modality, other cells could secrete enzyme with M6P into blood, and enzyme in blood could be taken up by cells in other organs via the M6PR. Indeed, neonatal administration of an adeno-associated virus vector, 11 γ-retroviral vector (RV 12, 13 ), or lenti-retroviral (lentiviral) vector 14 resulted in stable enzyme expression and prevented disease manifestations in many organs.
As most patients are not diagnosed at birth, it is important to achieve gene transfer in older animals. In contrast to the success with gene therapy in newborns, transduction of liver with γ-RV 12 or lentiviral vectors 14, 15 in adults had no therapeutic effect. This failure was probably due to the response of cytotoxic T lymphocytes (CTLs) to IDUA-expressing cells, as liver IDUA activity and vector DNA levels were low in two of these studies. 12, 14 The long-term expression in some mice that received HSC-directed gene therapy as adults 3 may be due to the ability of this procedure to induce tolerance to a transgene, although this approach results serum IduA activity after adult gene therapy An RV expressing canine IDUA (hAAT-cIDUA-WPRE) was injected intravenously into 6-week-old MPS I mice after induction of hepatocyte replication with hepatocyte growth factor (HGF). Although animals achieved 73 ± 54 (SD; N = 12) U/ml serum IDUA activity at 1 week, enzyme activity fell to low levels at 2-3 weeks (Figure 1a) . In an attempt to prolong the expression, three separate groups of mice were treated transiently with a single immunosuppressive agent. The Transient CTLA4-Ig group received four intraperitoneal doses of human CTLA4-Ig over 2 weeks, as indicated by the short bars at the top of Figure 1b . Serum IDUA activity was stable for 1-2 months but fell thereafter, although some mice maintained low expression that was clearly above the background activity. The Transient α-CD40L (Figure 1c) and Transient α-CD4 (Figure 1d ) groups received two doses of an α-mouse CD40L antibody or an α-mouse CD4 antibody, respectively, around the time of transduction. Serum IDUA activity was high at 1 week but fell later. The Prolonged CTLA4-Ig (Figure 1e ) group, which received adult gene transfer in conjunction with long-term administration of CTLA4-Ig, maintained IDUA activity at stable levels for up to 6.5 months, the duration of evaluation. The Transient CTLA4-Ig + α-CD40L (Figure 1f) and Transient CTLA4-Ig + α-CD4 (Figure 1g ) groups maintained stable IDUA activity for 6.5 months in 80 and 100% of mice, respectively. evaluation of immune response genes in spleens of adult and newborn mice To understand why mice produce a potent immune response to IDUA after adult, but not neonatal, gene therapy, RNA isolated from spleens collected at 3 days or at 6 weeks after birth was tested for levels of genes that are important for an immune response (Figure 2a) . Some mice received RV injection 24 hours before they were killed, whereas others received no treatment. As administration of the RV had very little effect upon RNA expression, values for all adults were pooled and compared with values for all newborns. The levels of RNA in adult mice relative to those in newborns were increased 7-fold for CD28 RNA (P = 0.007), 46-fold for CTLA4 (P = 0.004), 18-fold for CD40L (P = 0.002), 3-fold for CD4 (P = 0.03), 21-fold for CD8 (P = 0.03), 13-fold for IL-2 (P = 0.007), and 4-fold for IL-10 (P = 0.01). In contrast, the levels of RNA for IL-4 in adults were reduced to 18% of the levels in newborns (P = 0.03). Fluorescence-activated cell sorting demonstrated that 41 ± 6% of total splenocytes from 6-weekold mice were positive for CD3 (present on all T lymphocytes), 24 ± 6% were positive for CD4 (present on helper T cells, monocytes, and macrophages), and 12 ± 2% were positive for CD8 (present on cytotoxic or suppressor T cells and natural killer cells). The percentage of lymphocytes positive for CD3, CD4, and CD8 was reduced for newborn mice, at 6 ± 2, 3 ± 1, and 2 ± 1%, respectively. Thus, adults had sevenfold, sevenfold, and fivefold the percentage of CD3-, CD4-, and CD8-positive cells in total splenocytes compared with newborns (P < 0.001 for all comparisons).
Immunosuppression is transient
Reduction in responses to other antigens is a potential adverse effect of immunosuppressive agents. Mice that received transient immunosuppression were challenged with two doses of human factor IX (hFIX) with adjuvant starting at 6 months of age (4.5 months after gene transfer). They produced similar levels of anti-hFIX antibodies to age-matched normal or untreated MPS I mice (Figure 2b) . The mice that received prolonged CTLA4-Ig were not challenged in a similar fashion.
evaluation of the effect of gene therapy in adult MPs I mice
The second aim of this project was to determine whether adult gene therapy could prevent biochemical, pathological, and functional manifestations of disease. A total of 14 RV-treated mice showed stable expression, which included mice from the Prolonged CTLA4-Ig (N = 5), the Transient CTLA4-Ig + α-CD40L (N = 4), and the Transient CTLA4-Ig + α-CD4 (N = 5) groups. Their average serum IDUA activity was 81 ± 41 U/ml, with values ranging from 25 to 156 U/ml. These mice were evaluated biochemically, pathologically, and with specialized testing to determine whether disease was corrected at 8 months after birth, which was 6.5 months after transduction. As some mice were not Therefore, the hypothesis was that transduced hepatocytes would secrete IDUA and that M6P-modified IDUA in blood would diffuse into other organs and correct disease. For RV-treated mice with stable expression, IDUA activity was highest in liver, at 4.2 ± 2.2 U/mg (2.5-fold normal), whereas untreated MPS I mice had IDUA activity that was <1% of that in homozygous normal mice (Figure 3a) . Activity in other organs is organized from left (highest) to right (lowest) according to the relative levels of IDUA (U/mg) in RV-treated mice, and was >4% of normal activity in all organs except brain. These levels are predicted to have at least a partial therapeutic effect on lysosomal storage, as the enzyme activity in fibroblasts from patients with Scheie syndrome is usually ≤7% of normal. 27 IDUA activity in brain was 0.02 ± 0.02 U/mg, which was 3% of the value in normal mice (P < 0.01 for RV-treated versus normal mice) and fourfold the value in untreated MPS I mice (P is not significant for RV-treated versus MPS I mice).
β-Hexosaminidase ( β-hex) activity MPS I results in an elevation in the activity of other lysosomal enzymes, and normalization of this elevation by effective treatment correlates with pathological improvements in lysosomal storage. In general, the total β-hex levels in untreated MPS I mice in this study were lower than in our previous study. 13 This may have been due to the use of a kinetic fluorometer here, which eliminates the need to dilute samples with high activity to achieve an accurate reading as was done in our previous study. β-Hex activity was significantly increased in samples from MPS I mice to 3-to 23-fold the levels found in normal mice in liver, testis, kidney, heart, small intestine, muscle, aorta, and ovary (Figure 3b ; P < 0.05 versus normal). β-Hex activity was significantly reduced in RV-treated mice with stable expression as compared with MPS I mice in all of these organs (P < 0.05). β-Hex activity was not statistically elevated in untreated MPS I mice as compared with normal mice in spleen, thymus, large intestine, lung, or brain.
GAG levels
Deficient IDUA enzyme activity leads to accumulation of dermatan and heparan sulfate, and effective treatments can reduce GAG levels. As shown in Figure 3c , GAG levels in most organs were significantly increased in untreated MPS I mice to values that were 2-to 100-fold those in normal mice (P < 0.01) and were significantly reduced in most organs, to normal or near-normal values, in RV-treated mice with stable expression (P < 0.01 for RV-treated versus MPS I mice; P is not significant for RV-treated versus normal mice). However, the GAG levels of 24 ± 12 µg GAG/mg protein in aorta of RV-treated mice remained markedly elevated at 48-fold the value in normal mice (P < 0.05) and were 58% of those in untreated MPS I mice (not significant). GAG levels were not elevated in brain of untreated MPS I mice and could, therefore, not be used to evaluate lysosomal storage in RV-treated mice.
Pathological analysis for lysosomal storage
The amount of lysosomal storage on toluidine blue-stained thin sections was scored from 0 (normal) to 3 (severe storage), as detailed in Table 1 , which also shows the average lysosomal storage pathology scores and statistical comparisons between different groups. Lysosomal storage was completely or substantially corrected in liver, testis, spleen, thymus, kidney, small intestine, ovary, and lung. The amount of lysosomal storage in eye, aorta, heart, and brain is discussed below.
Bone
The femurs and humeri were 139 ± 3% and 147 ± 3% as wide in MPS I mice as in heterozygous normal mice (P < 0.01) ( Figure 4a and Table 2 ). RV-treated mice with stable expression had statistically significant reductions to 108 ± 8% and 114 ± 9% of normal, although the average values remained statistically higher than in normal mice. Figure 4b and c demonstrates that the width of the femur and humerus of RV-treated mice with stable expression was strongly inversely proportional to the serum IDUA activity, with R 2 values of 0.39 and 0.38, respectively (P = 0.02 for a statistically significant correlation between the serum IDUA activity and bone widths). Untreated MPS I mice had increased bone mineral density (BMD) at 0.069 ± 0.005 gm/cm 2 , whereas RV-treated mice with stable expression had normal BMD at 0.053 ± 0.004 gm/cm 2 ( Table 2 ). The BMD in RV-treated mice was moderately inversely proportional to the serum IDUA activity, with an R 2 value of 0.24 (Figure 4d ; P = 0.05).
Hearing
The threshold to elicit a neurological signal in an auditoryevoked brainstem response at a sound frequency of 5 kHz was 84 ± 6 dB for MPS I mice, which was significantly higher than in normal mice (40 ± 11 dB; P < 0.01; Figure 4e and Table 2 ). RV-treated mice with stable expression had a statistically significant improvement in hearing, as their threshold was 65 ± 21 dB (P < 0.05 versus MPS I), although this remained higher than in normal mice (P < 0.01). There was a very strong inverse correlation between the serum IDUA activity in individual RV-treated mice and the hearing threshold at 5 and 10 kHz, 
Vision
The initial hyperpolarization (a-wave) in response to light in a dark-adapted flash electroretinogram reflects photoreceptor function, and the depolarization that follows (b-wave) indicates function of photoreceptors and secondary neurons. 28 The a-and b-wave amplitudes in MPS I mice (Figure 5b ) were 125 ± 51 and 452 ± 155 µV, respectively, which were significantly lower than the amplitudes of 346 ± 38 and 735 ± 88 µV in normal mice (Figure 5a and Table 2 ). RV-treated mice with stable expression had a-and b-wave amplitudes of 220 ± 63 and 620 ± 69 µV, which was statistically better than in untreated MPS I mice but statistically worse than in normal mice. There was a poor correlation that failed to show statistical significance between the serum IDUA activity and the amplitudes of the a-and b-waves in RV-treated mice with stable expression: R 2 values of 0.11 and 0.18, respectively (Figure 5e and f) . The outer nuclear layer of the retina from MPS I mice had only 6.3 ± 0.8 nuclei per thickness, which was fewer than the 10.3 ± 0.6 in normal mice (Figure 5i and j, and Table 1 ). Although the average number of nuclei in the outer nuclear layer for RV-treated mice with stable expression was still reduced, at 7.5 ± 1.2, and was not statistically improved from the values in untreated MPS I mice ( Table 1) , there was a strong direct correlation between the serum IDUA activity and number of nuclei in RV-treated mice, with an R 2 value of 0.44 (Figure 5g ; P = 0.02). Figure 5h and n and Table 1 demonstrate that the cornea from an MPS I mouse had substantial amounts of lysosomal storage in the stroma (scored as 3), which was absent in a normal mouse (scored as 0). Although the average cornea pathology score of 2.1 ± 0.9 in RV-treated mice with stable expression was not statistically better Adult Gene Therapy for MPS I Mice than in untreated MPS I mice, there was a moderate inverse correlation between the cornea pathology score and the serum IDUA activity (Figure 5h) , with an R 2 value of 0.34 (P = 0.03).
Heart
Lysosomal storage was mild or absent in the aortic valves and the cardiac parenchyma of RV-treated mice with stable expression (Figure 5s and t and Table 1 ). However, the aortas of most RV-treated mice with stable expression had large amounts of lysosomal storage material (Figure 5w) , although one of the nine mice had a marked reduction (Figure 5x) . Indeed, the average lysosomal storage pathology score of 2.6 ± 0.9 in the aorta was not significantly better than the value in untreated MPS I mice ( Table 1) . Furthermore, most RV-treated mice had elastic fiber fragmentation, and the average aortic diameter of 2.4 ± 0.5 mm ( Table 2) was not statistically different from that in untreated MPS I mice (2.8 ± 0.7 mm) and was wider than in normal mice (1.8 ± 0.3 mm; P < 0.01). Finally, 56% of RV-treated MPS I mice had aortic insufficiency, which was not statistically lower than the value of 73% in untreated MPS I mice ( Table 2) . We conclude that storage is reduced in the aortic valves and parenchyma of RV-treated mice with stable expression but remains severe in the aorta.
Brain
Untreated MPS I mice had substantial amounts of lysosomal storage in perivascular cells, the meninges, and the choroid plexus, with lysosomal storage pathology scores of 3.0 ± 0, 3.0 ± 0, and 2.5 ± 0.5, respectively ( Table 1) . Lysosomal storage was partially improved in the perivascular cells of RV-treated mice with stable expression, although it was not significantly reduced in the meninges. Lysosomal storage was completely absent in the choroid plexus of two RV-treated mice with stable expression, although the small number of samples with this region limited statistical evaluation. Large pyramidal neurons in the cortex and the hippocampus of untreated MPS I mice had substantial amounts of lysosomal storage (Figure 6b and f) , resulting in an average pathology score of 3.0 ± 0 in both regions (Table 1) . Furthermore, 63 ± 27 and 77 ± 25% of the neurons in the cortex and hippocampus of MPS I mice contained at least three small white vacuoles that were consistent with lysosomal storage (Figure 6m and n, respectively, and Table 1 ). RV-treated mice with stable expression had partial or marked reductions in storage in neurons of the cortex and hippocampus for animals with serum activity of <100 U/ml (Figure 6c and g ) or >100 U/ml (Figure 6d and h) , respectively, Abbreviations: ABR, auditory-evoked brainstem response; IDUA, α-l-iduronidase; MPS I, mucopolysaccharidosis; NS, not significant; RV, retroviral vector. Shaded rows indicate tests where RV-treated mice with stable expression were significantly better than untreated MPS I mice. a Mice were treated as described in Figure 1 , and means ± SD were determined at 8 months. The number of animals in each group (N) and the average serum IDUA activity for RV-treated mice with stable expression that were evaluated for each test are shown. Fisher's exact test was used to determine whether the frequency of aortic insufficiency was significantly different. resulting in reduced lysosomal storage pathology scores and fewer neurons with storage ( Table 1) . The percentage of neurons with lysosomal storage in the cortex and the hippocampus of RV-treated mice was strongly inversely correlated with the serum IDUA activity, with R 2 values of 0.76 (P = 0.005) and 0.63 (P = 0.02), respectively (Figure 6m and n) . Most RV-treated mice with stable expression had no improvement in storage in the Purkinje cells ( Table 1) as shown for a representative example (Figure 6k) , although the mouse with the highest IDUA activity had reduced lysosomal storage (pathology score of 1; Figure 6l ).
Analysis of rV dnA and rnA in the brain and other organs
The liver contained 13.8 ± 7.4 copies of RV per 100 cells and RV RNA levels were 8.5 ± 2.1% of β-actin RNA levels at 1 week after transduction (Figure 6o and p) . Spleen DNA and RNA levels were 6 and 11% of those in liver, respectively, demonstrating that the vector was not liver specific and that antigen-presenting cells may have been transduced. At 6.5 months after transduction, RV DNA and RNA copies remained high in liver, and spleen contained 5 and 6% as much DNA and RNA, respectively, as liver. The RV was also expressed at low levels in bone marrow at 0.01 ± 0.01% β-actin levels (0.4% of liver) and in blood cells at 0.002 ± 0.002% β-actin levels (0.1% of liver). The identification of RV RNA in bone marrow and blood cells, which did not contain detectable RV DNA copies, was likely due to the greater sensitivity of the RNA assay. RV RNA and DNA were undetectable in brain. dIscussIon stable expression of cIduA in MPs I mice required immunosuppression The reduction in IDUA activity in serum and organs that we and others have observed after gene transfer to adult MPS I mice is likely due to a CTL response, as anti-canine IDUA antibodies were not detected and the RV DNA levels were very low in the liver. 12 Furthermore, serum levels of the liver enzyme alanine aminotransferase, a marker of liver damage, were elevated at 14 days after transduction in RV-treated mice that did not receive immunosuppression at 73 ± 31 U/L (N = 6). This was 2.1-fold the level in RVtreated mice that were effectively treated with immunosuppression (34 ± 4, N = 4; P < 0.01; data not shown) and 3-fold the level in untreated MPS I mice of 24 ± 8 U/L (N = 5). In addition, the livers of RV-treated mice that did not receive immunosuppression contained lymphocytic infiltrates at 14 days (data not shown).
The approach that was taken here to prevent an immune response after gene therapy to adults was to block co-stimulation and/or deplete CD4 cells. Blockade of co-stimulation is intellectually appealing, as cells that encounter antigen in the absence of co-stimulation can undergo apoptosis, 18 resulting in clonal deletion and long-standing tolerance after a short period of drug administration. Adult spleens had 7-and 18-fold as much CD28 and CD40L RNA, respectively, as newborns, suggesting that both of these co-stimulatory pathways may potentiate an immune response in adults. The combination of CTLA4-Ig with α-CD40L antibody prevented an immune response to IDUA in most adult animals, which is consistent with the results of others in organ transplantation (reviewed in ref. 18) or gene therapy for hemophilia A. 22 Adult spleens also had threefold more CD4 RNA and a sevenfold higher percentage of CD4 + cells in the spleen than newborns; the discrepancy in the magnitude of the difference may be because adult splenocytes had only 65% as much cellsurface CD4 as newborn splenocytes (data not shown). The combination of CTLA4-Ig with the α-CD4 antibody was effective in preventing an immune response to IDUA after adult gene therapy in this study. Mice that received transient immunosuppression were not immunocompromised 4.5 months later, as they mounted a normal antibody response to hFIX. Although administration of CTLA4-Ig alone for 6.5 months was effective, it would likely result in substantial immunosuppression. It remains possible that administration of CTLA4-Ig for an intermediate period might be effective long term.
An alternative approach to reduce an immune response after gene transfer to adult MPS I mice was to avoid expression from a lentiviral vector in antigen-presenting cells using the liver-restricted albumin promoter. 17 However, there was only ~1% of normal IDUA activity in liver and spleen, and a recent report suggested that a similar construct was leaky and evoked an immune response to green fluorescent protein. 29 In this study, some animals that received a single immunosuppressive agent and had a decrease in serum IDUA activity to <1% of the initial activity still had detectable serum IDUA activity. Furthermore, all mice with unstable expression had liver IDUA activity that was >1% of normal and liver RV RNA that was above the background, albeit low at 0.15% of the level found in mice with stable expression (data not shown). We propose that some cells with very low expression may escape a CTL response and that detectable enzyme activity and/or vector RNA levels do not exclude the possibility of an immune response. Mice with unstable expression had partial improvements in bone widths and BMD but no improvements in auditory-evoked brainstem response, electroretinograms, or echocardiograms (data not shown).
lysosomal storage is reduced in organs
The main goal of this study was to determine whether gene therapy to adult mice could correct the biochemical and clinical manifestations of MPS I. Serum IDUA activity in RV-treated mice of 25-156 U/ml was associated with reductions in biochemical and/ or pathological evidence of lysosomal storage in all mice in liver, testis, spleen, thymus, kidney, small intestine, ovary, and lung, which should reduce hepatosplenomegaly and improve fertility, and may reduce gastrointestinal and pulmonary symptoms.
Improvements in bone, ear, and eye, but not in aorta
In this study, RV-treated mice with stable expression had statistically significant improvements in long bone widths, hearing, BMD, and vision, with serum IDUA activity >100 U/ml conferring greater benefits than activity <100 U/ml. Reduced bone widths may contribute to improved hearing, as bone thickening probably contributes to the conductive defect. 30 In contrast, lysosomal storage and dilatation of the aorta remained severe. The dense structure of the aorta may make it difficult for IDUA to diffuse to the interior, or aortic smooth muscle cells may have low levels of the M6PR.
The failure to correct manifestations completely could be due to initiation of treatment after disease had developed or to the relatively low average serum IDUA activity of 81 ± 41 U/ml. We favor the latter hypothesis, as evaluation of bones, hearing, vision, eye, and aorta were normal or near-normal in MPS I mice at 6 weeks of age (X.M., J.A. Metcalf, A.H., R. Knutsen, R. Mecham, M.T., and K.P.P., unpublished data). In addition, in our previous study on gene therapy in newborns, mice that achieved only 30 U/ml had some defects in all of these parameters, whereas those that achieved 1,000 U/ml were almost completely corrected. 12 We estimate that the target serum IDUA activity for improvement of young adult mice is >100 U/ml in bone and hearing, >200 U/ml for vision and eye, and >500 U/ml for aorta.
Brain
Evaluation of brain is important, as patients with Hurler syndrome have neurological impairment. RV-treated mice with stable expression had reductions in lysosomal storage pathology in perivascular cells, pyramidal neurons of the cortex and hippocampus, and the choroid plexus. Improvements were greater in RV-treated mice with >100 U/ml of IDUA activity in serum than in those with <100 U/ ml. However, most RV-treated mice still had severe storage in the meninges and Purkinje cells. As the brain was almost completely corrected after neonatal gene therapy in mice with 1,000 U/ml of serum IDUA activity, but was only partially improved in mice with 30 U/ml, 12 the failure to correct disease completely in brain in this study may be due to insufficient IDUA activity in blood rather than the late age at therapy. A reasonable target for serum IDUA activity for correction of brain disease after adult gene therapy is >500 U/ml.
It was surprising that lysosomal storage was reduced in brain, as it has been a long-standing belief that enzyme in blood cannot cross the blood-brain barrier in adults. However, a recent study demonstrated that ERT to adults reduced lysosomal storage in neurons in MPS VII mice, 31 and neonatal gene therapy approaches in which nucleic acid levels were undetectable 11 or were very low 13 in brain reduced lysosomal storage in MPS I mice. Indeed, in this study, RV RNA levels were undetectable in the brain using a very sensitive real-time reverse transcriptionpolymerase chain reaction assay. We therefore favor the hypothesis that improvements were due to enzyme diffusion from blood into the brain. It is unclear why Purkinje cells and meninges were relatively refractory to treatment. It is possible that they contain low levels of the M6PR. A future study will evaluate whether RV-treated MPS I mice have improved neurological function in an open field test of habituation.
11
Implications for patients with MPs I These results hold out the promise that gene therapy may be feasible and efficacious in older MPS I patients with null mutations if transient immunosuppression is given. CTLA4-Ig was recently approved for use in humans with rheumatoid arthritis as the drug called Orencia (abatacept; Bristol-Myers-Squibb, Princeton, NJ). Although α-CD40L antibodies have resulted in thromboembolic events in human trials and will probably not be pursued further, 32 an α-CD40 antibody, which blocks the same pathway, was effective at prolonging graft survival in non-human primates in conjunction with CTLA4-Ig. 33 In a similar way, an α-CD4 antibody blocked immune responses in non-human primates. 34 It is also possible that immunosuppressive agents that are routinely used in patients such as cyclosporine and azathioprine could be effective, as a 2-month course prevented an antibody response to IDUA protein in MPS I dogs. 25 The risks of gene therapy also need to be considered, as liver cancers developed in some mice that received neonatal or fetal injection of some, but not other, lentiviral vectors. 35 It is reassuring that we have not seen tumors with our vector in any of more than 100 mice that have been followed long term (data not shown). In addition, leukemia or lymphoma developed in some human patients and in a non-human primate that received HSC-directed gene therapy. 36 As the latter malignant transformation was associated with transduction of hematopoietic cells, the low transduction efficiency of bone marrow and blood cells in our study should reduce this risk. Nevertheless, it will be important to continue to evaluate animals for evidence of toxicity before implementing this gene therapy approach in humans.
